IL-22 promotes the progression of breast cancer through regulating HOXB-AS5

Abstract

Interleukin-22 (IL-22) is a well-known tumor related inflammatory factor that is associated with variety of cancers. HOXB-AS5, a long non-coding RNA located in HOX gene clusters, has been elevated in breast cancer (BC) tissues. Herein, IL-22 and HOXB-AS5 were upregulated in the serum and tissues of BC patients and were associated with clinical stages. Furthermore, we also investigated the effects of IL-22-HOXB-AS5 pathway on progression of BC, and the results suggested that IL-22 and HOXB-AS5 synergistically promoted MDA-MB-231 cell growth, migration and invasion and activated the PI3K-AKT-mTOR pathway. These findings demonstrated that the IL-22-HOXB-AS5-PI3K/AKT functional axes may serve as potential molecule biomarkers for diagnosis and therapy evaluation or targeted therapeutic strategy in BC.

Long noncoding RNA HOXB13‐AS1 regulates HOXB13 gene methylation by interacting with EZH2 in glioma

“…Subsequent studies showed that HOXB13‐AS1 was highly expressed in human prostate, uterus, distal colon, and stomach tissues . Moreover, another study also reported that HOXB13‐AS1 promoted breast cancer initiation and progression by activating PI3K‐AKT‐mTOR pathway . However, the expression and biological roles of HOXB13‐AS1 in glioma have not been fully characterized.…”

“…30,31 Moreover, another study also reported that HOXB13-AS1 promoted breast cancer initiation and progression by activating PI3K-AKT-mTOR pathway. 32 However, the expression and biological roles of HOXB13-AS1 in glioma have not been fully characterized. Because of the higher expression and function roles of HOXB13-AS1 in human cancer attracted us to choose HOXB13-AS1 as the focus to investigate in this study, we thereby considered whether the overexpression of HOXB13-AS1 gene was associated with glioma tumorigenesis.…”

Interleukin‐22 promotes development of malignant lesions in a mouse model of spontaneous breast cancer

“…In breast cancer, elevated levels of IL-22 are reported in serum and tumor tissues (Rui et al, 2017;Voigt et al, 2017). However, it is not clear whether these elevated levels are associated with a particular stage of cancer progression.…”

“…In cancer, the role of IL-22/IL-22RA1 axis is complex and contextdependent. Elevated levels of IL-22 are reported in cancer patients and associated with poor survival rate (Rui et al, 2017;Voigt et al, 2017). IL-22 stimulates STAT-3-mediated cell proliferation and stemness in cancer cells in colon, liver, gastric, pancreatic, and lung cancers (Lim and Savan, 2014).…”

“…In breast cancer, relatively few studies have been performed to understand the role of IL-22 in disease pathogenesis. The current knowledge of IL-22 function is based on advanced-stage cancer cell line models where it has been shown that IL-22 stimulates cell proliferation, transformation, and migration in human/mouse cancer cell lines (Kim et al, 2014;Rui et al, 2017;Wang et al, 2018). Voigt et al have recently demonstrated that inhibition of IL-22 production through IL-1R antagonist anakinra can reduce tumor burden in a transplant tumor model and identified Th22 cells as a primary source of IL-22 in breast cancer.…”